MannKind Q1 2023 total revenues $40.6M (+239% YoY); Tyvaso DPI drives $23M

MANNKIND CORP

2023-Q1 EPS reported -$0.04 revenue$40,626,000

Total revenues $40.6M vs $12.0M in Q1 2022, a 239% increase.
Tyvaso DPI contributed $23M in revenue (collaborations/services $11.4M, royalties $11.7M).
Afrezza net revenue $12.4M (+26% YoY); V-Go added $5.1M (acquired mid-2022).
Loss from operations improved 72% to $6M; cash and investments $166.6M at March 31.
CEO cites strong Tyvaso DPI demand; Phase 2/3 inhaled clofazimine trial to start H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MANNKIND CORP reported the quarter ended March 31, 2023 results: revenue $41 million.

Period: the quarter ended March 31, 2023
Revenue: $41 million
Result: reported results

Exact text from the filing

(EX-99.1) --- EX-99 EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2023 FIRST QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) • 1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022 • 1Q 2023 Revenues associated with Tyvaso DPI of $23 million • 1Q 2023 Loss from operations decreased 72% vs. 1Q 2022 to $6 million • $167 million of Cash,

View on SEC.gov

Browse all earnings releases →

MANNKIND CORP filing history →

Source: SEC EDGAR

accession 0000950170-23-019629

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.